Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with <i>FGFR1</i> mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Authors: Carmen Calfa, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene Ahn, Keerthi Gogineni, Nitin Rohatgi, Monika L. Burness, Anu Gaba, Omid Hamid, Tareq Albaghdadi, Alison Conlin, Philip Gold, Jordi Rodon, Ramya Thota, Richard L. Schilsky

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-ct173

Source: Full article